Climb Bio (NASDAQ:CLYM) used an investor R&D spotlight event to outline its strategy around CD19-targeted B-cell depletion ...

A significantly greater percentage of patients achieved complete remission with obinutuzumab vs with tacrolimus at 104 weeks. Topline results were announced from a phase 3 trial evaluating ...

Vertex stock skidded Tuesday on a mixed first-quarter report, but analysts remain more interested in the company's R&D plans.

On May 5, 2026, Climb Bio held a virtual R&D Spotlight investor event to showcase progress on budoprutug, its clinical-stage anti-CD19 monoclonal antibody for primary membranous nephropathy, immune ...

Several immunosuppressive treatments have demonstrated their efficacy in idiopathic membranous nephropathy, but spontaneous remission does develop in more than 30% of patients. The availability of a ...

PHILADELPHIA -- Researchers may have found another autoantigen involved in idiopathic membranous nephropathy, they reported here. In a study of 154 patients who did not have antibodies to PLA2R1 -- ...

Research conducted by a pair of physicians has led to the development of a test that can help diagnose membranous nephropathy in its early stages. The test, which is currently only offered in the ...

Daniel C. Cattran, MD The MENTOR study is poised to change first-line-treatment recommendations for idiopathic membranous nephropathy. The Membranous Nephropathy Trial of Rituximab (MENTOR) study is ...

It is crucial to differentiate between the two forms because delays in treatment may lead to substantial or potentially permanent complications. One third of patients develop persistent nephrotic ...

Renal disease is a major cause of mortality and morbidity in systemic lupus erythematosus. Among the histological classes of lupus nephritis, membranous nephropathy comprises only one-fifth of all ...